Mini-Review: Recent Advances in Aptamer Applications
Gerald Zon*
TriLink BioTechnologies, 10770 Wateridge Circle, Suite 200, San Diego, California, 92121, USA
Aptamers, which are short strands of synthetic DNA or RNA selected for binding to target ligands, have proven useful for cell-specific delivery, detection, or both. This mini-review presents selected examples of these applications for cancer published during 2019 – September 2020.
DOI: 10.29245/2578-2967/2020/3.1186 View / Download Pdf Patient Reported Outcomes after Cannabis Use to Control Symptoms
Cary A. Presant1*, Shanmuga Subbiah1, Gargi Upadhyaya1, Meizi Zheng1
1City of Hope Medical Center, West Covina, CA, USA
In order to determine the frequency of cannabis product (marijuana, THC or CBD) use and determine the patient reported outcomes to control symptoms, an anonymous survey of cannabis product use was conducted in patients who had cancer, non-malignant hematologic disorders or other diseases. Patients reported the degree of control of symptoms using a Likert scale. The use of cannabis products was 23.3% (36 users in 154 patients). This did not vary by age, gender, or disease. Use was predominately CBD in patients over 65, but was either marijuana, THC or CBD in younger patients. Patients reported some degree of control of at least one symptom in 91.9%, and high degree of control in 51.7% of patients. Most patients relied on recommendations of family or friends to try cannabis, but only 4% relied on clinician advice. 53% of patients said they were willing to consider participating in a prospective clinical trial of cannabis products to control symptoms. We conclude that cannabis product use is frequent in cancer patients. Physicians should obtain a detailed history of cannabis product use in patients, and could consider a therapeutic trial of cannabis products in selected patients with symptoms not controlled by usual treatments. Clinicians may need additional education to provide the highest level of evidence-based support for cannabis product use in patients in need of symptom control.
DOI: 10.29245/2578-2967/2020/4.1188 View / Download Pdf